a pink-and-white flamingo and paisley pattern that adorns items from clothing to home accessories, the brand said. Lilly Pulitzer, which was created in the 1960s by its eponymous founder who ...

Online boutique Pink Lily shared on social media they are moving their headquarters to Nashville. Owner Tori Gerbig ...

New results show Eli Lilly and Company's (NYSE: LLY) EBGLYSS improved skin (including hand and face) and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously ...

Upgrade to begin using 40 years of financial statements and get so much more. Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all ...

Oct 2 (Reuters) - U.S. drugmaker Eli Lilly (LLY.N), opens new tab said on Wednesday it will invest $4.5 billion to create a new center in Indiana that will focus on developing new ways to ...

Eli Lilly & Co. is pouring $4.5 billion into a new manufacturing plant in Indiana to make drugs for future clinical trials, part of a broader push to shore up the company’s supply chain.

Earnings Report 1.453 USD Q3 2024 Earnings Release 10/30/2024 Earnings Report 5.438 USD Q4 2024 Earnings Release 01/30/2025 Earnings Report 5.271 USD Q1 2025 Earnings Release 04/24/2025 Earnings ...

Pharmaceutical giant Eli Lilly (LLY) is putting $4.5 billion toward building a new site to develop and manufacture drugs. The Lilly Medicine Foundry, located in Lebanon, Indiana, is a first-of-its ...

Oct 2 (Reuters) - The U.S. Food and Drug Administration removed Eli Lilly's (LLY.N), opens new tab blockbuster weight-loss and diabetes drugs from its shortage list late on Wednesday, likely ...

Eli Lilly (NYSE:LLY) is reportedly looking to study its popular weight-loss drug Zepbound in people who aren't considered overweight but are still at risk for developing conditions such as diabetes.

Eli Lilly has finally made enough supply of its popular medicine tirzepatide to meet soaring demand, which should help the company widen its share of the booming weight-loss drug market.

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Times are good at Eli Lilly. Wall Street’s insatiable appetite for weight-loss drug stocks looks set to ...